Shi Ru, Qi Wenjuan, Wang Zehua, Cai Jing, Zhao Min, Wang Zanhong
Department of Obstetrics and Gynecology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Department of Obstetrics and Gynaecology, Shanxi Children's Hospital, Shanxi Maternal and Child Health Hospital, 13Xinmin North Street, 030001, Taiyuan, Shanxi, China.
Sci Rep. 2025 Aug 2;15(1):28217. doi: 10.1038/s41598-025-14228-0.
To characterize the hrHPV genotype distribution and attribution to cervical lesions in the cohort of women screened in Shanxi Province. Data from the records of cervical cancer screening programs for rural women in Shanxi Province were retrospectively collected. Women who underwent primary human papillomavirus (HPV) screening between January 2014 and December 2019 were included. The attribution proportion of specific hrHPV types for different grades of cervical lesions was calculated by using the type contribution weighting and the proportional attribution methods to estimate the potential impact of HPV vaccines on CIN II + lesions. CIN II + lesions were observed mainly with HPV16 (65.85%), HPV18 (10.20%), HPV58 (10.20%), HPV52 (7.98%), HPV31 (4.66%), HPV33 (4.43%), HPV51 (2.22%) and HPV56 (2.22%). A total of 97.42% of all CIN II + lesions were attributed to HPV16, HPV18, HPV52, HPV58, HPV31, HPV33 and HPV35. A total of 75.4% (95% CI, 71.4-79.3) of CIN II + lesions were attributable to HPV16/18, and 21.1% (95% CI, 17.4-25.1) were attributable to the 5 additional types (HPV31/33/45/52/58) covered by the 9-valent vaccine. The prevalence of hrHPV infection among women in Shanxi Province was high, and HPV16, HPV18, HPV58, HPV52, HPV31, HPV33 and HPV35 had the highest attributable proportion of CIN II + lesions. The type-specific HPV prevalence and attribution proportion of cervical precancerous lesions should be taken into consideration in both clinical management and the design of preventive strategies.
为了明确山西省接受筛查的女性队列中高危型人乳头瘤病毒（hrHPV）的基因型分布及其与宫颈病变的关系。回顾性收集了山西省农村女性宫颈癌筛查项目记录中的数据。纳入了2014年1月至2019年12月期间接受初次人乳头瘤病毒（HPV）筛查的女性。采用型别贡献加权法和比例归因法计算不同级别宫颈病变中特定hrHPV型别的归因比例，以评估HPV疫苗对CIN II+病变的潜在影响。CIN II+病变主要与HPV16（65.85%）、HPV18（10.20%）、HPV58（10.20%）、HPV52（7.98%）、HPV31（4.66%）、HPV33（4.43%）、HPV51（2.22%）和HPV56（2.22%）相关。所有CIN II+病变中，共有97.42%归因于HPV16、HPV18、HPV52、HPV58、HPV31、HPV33和HPV35。共有75.4%（95%CI，71.4-79.3）的CIN II+病变归因于HPV16/18，21.1%（95%CI，17.4-25.1）归因于9价疫苗涵盖的另外5种型别（HPV31/33/45/52/58）。山西省女性中hrHPV感染率较高，HPV16、HPV18、HPV58、HPV52、HPV31、HPV33和HPV35在CIN II+病变中的归因比例最高。在临床管理和预防策略设计中均应考虑宫颈癌前病变的型别特异性HPV流行率和归因比例。
